52 reports

Interferon is mainly divided into ordinary interferon and long-acting interferon.

  • Hepatitis
  • Interferon
  • Medical Biotechnology
  • China
  • Market Size

Interferon Gamma-##B Sales, Price Analysis, & Sales Forecast - 2017 ##.

  • Interferon
  • Medical Biotechnology
  • World
  • Demand

Interferon Beta-##B Sales, Price Analysis, & Sales Forecast - 2017 ##.

  • Interferon
  • Medical Biotechnology
  • World
  • Demand

Interferon Beta-##A Sales, Price Analysis, & Sales Forecast - 2017 ##.

  • Interferon
  • Medical Biotechnology
  • World
  • Demand

Interferon Alfa-##B Sales, Price Analysis, & Sales Forecast - 2017 ##.

  • Interferon
  • Medical Biotechnology
  • World
  • Demand
  • Interferon
  • Interferon Sales and Forecasts (Billion Yuan)

The auto exports exceeded over ## million each year.

  • Diagnostics
  • Interferon
  • Medical Biotechnology
  • China
  • Demand
  • Recombinant Interferon
  • Recombinant Interferon Production and Demand

During the last decade, China' s output of the recombinant interferon enjoyed a rapid growth rate, increasing by ##. ##% average per annum, which makes China one of the largest consumption countries of recombinant interferon in the world.

  • Interferon
  • China
  • Demand
  • Supply
  • Shenzhen Keing Biotech Co., Ltd
  • Interferon Sales Volume (Million Yuan)
  • Interferon Major Producer and Their Market Share

The auto exports exceeded over ## million each year.

  • Interferon
  • China
  • Demand
  • Bayer Schering Pharmaceutical Co., Ltd
  • Changchun ChangSheng Gene Pharmaceutical Co., Ltd.
  • Interferon
  • Interferon Sales Volume (Million Yuan)

The auto exports exceeded over ## million each year.

  • Interferon
  • China
  • Demand
  • Harbin Pharmaceutical Group
  • North China Pharmaceutical Group Corp.
  • Interferon Major Producer and Their Market Share
  • Interferon Sales Volume (Million Yuan)

Immunotherapy Drugs Sales Volume α-Interferon Sales Volume ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## Zhejiang Beisheng Medicine Industry Hansheng Pharmaceutical Co., Ltd.

  • Interferon
  • China
  • Demand
  • Bayer Schering Pharmaceutical Co., Ltd
  • Changchun ChangSheng Gene Pharmaceutical Co., Ltd.
  • Interferon
  • Interferon Sales Volume (Million Yuan)

It is the leading brand in interferon market of China.

  • Interferon
  • China
  • Demand
  • Harbin Pharmaceutical Group
  • North China Pharmaceutical Group Corp.
  • Interferon
  • Interferon Sales and Forecasts (billion Yuan)

Table ##: Interferon Sales and Forecasts (billion Yuan) Chapter IV Chapter IV BIOLOGICS SALES VOLUMES AND FORECASTS Chart ##: Interferon Sales and Forecasts (Billion Yuan) Antitoxin An antitoxin is an antibody with the ability to neutralize a specific toxin.

  • Interferon
  • China
  • Demand
  • Market Size
  • Dongguan Winnerway Bio-Tech Co., Ltd.
  • Interferon
  • Interferon Import

The auto exports exceeded over ## million each year.

  • Interferon
  • China
  • Trade
  • Lijun Pharmaceutical Co., Ltd.
  • Shanghai Schering-Plough Pharmaceutical Company, Ltd
  • Recombinant Interferon Production and Demand
  • Recombinant Interferon Output and Demand (Million

IN DOMESTIC MARKET, THERE ARE MAINLY TWO KINDS OF RECOMBINANT INTERFERON, DOMESTIC INTERFERON AND IMPORTED INTERFERON.

  • Interferon
  • China
  • Demand
  • Market Size
  • Supply
  • HEPATITIS C THERAPEUTICS MARKET, GLOBAL, LICENSING DEALS BY MOLECULAR TARGETS AND
  • HEPATITIS C THERAPEUTICS, GLOBAL, CLINICAL TRIAL SIZE PER PRODUCT BY MOLECULAR TARGET

Interferon alpha binds to interferon receptors.

  • Interferon
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • Roche Group

Global Interferon Market & Pipeline Analysis 2015 ##.

  • Biopharmaceutical
  • Interferon
  • Medical Biotechnology
  • World
  • Interferon Alpha (IFNA) - Discontinued Products
  • Interferon Alpha (IFNA) - Dormant Projects

With a prevalence between ## in ##, ## and ## in ##, ## cases, DM is considered an orphan disease both in North America and in Europe.

  • Interferon
  • Musculoskeletal Disorder
  • Therapy
  • United States
  • Neovacs SA
  • interferon alpha - Drug Profile
  • Human Parainfluenza Virus 3 Infections - Pipeline by Amarillo Biosciences Inc, H2 2018

The molecules developed by Companies in Phase II, Phase I and Preclinical stages are ##, ## and ## respectively.

  • Interferon
  • Therapy
  • United States
  • World
  • Product Initiative
  • NUMBER OF PRODUCTS BY STAGE AND TARGET, H2 2019
  • NUMBER OF PRODUCTS BY STAGE AND MECHANISM OF ACTION, H2 2019

LOWR- ## (LonafarnibWith and withoutRitonavir-##)was a parallel dose comparison study which randomized subjects to receive different doses of lonafarnib with or without ritonavir or pegylated interferon for four to twelve weeks.

  • Hepatitis
  • Interferon
  • United States
  • Product Initiative
  • REPLICor Inc.
  • Target
  • Completion

Negrin University Hospital Asociacion Científica Pulmon y Ventilacion Mecanica ## Apr 2013 ## Mar 2013 ## Oct 2018 ## Feb 2019 ## ## ## ## ## Glucocorticoid Receptor (GR or Nuclear Receptor Subfamily ## Group C Member ## or NR##C##) Agonist Glucocorticoid Receptor (GR or Nuclear Receptor Subfa

  • Interferon
  • Pharmaceutical
  • Therapy
  • World
  • Product Initiative
  • Clinical Trial profile. 85 Trial Title

## ## ## ## ## ## Germany ## ## ## ## ## ## ## ## Canada ## ## ## ## ## ## ## ## Japan ## ## ## ## ## ## ## ## Italy ## ## ## ## ## ## ## ## France ## ## ## ## ## ## ## ## United Kingdom ## ## ##

  • Clinical Trial
  • Dermatological Condition
  • Interferon
  • Medical Biotechnology
  • Merck & Co., Inc.
  • Target
  • Clinical Trial profile. 173 Trial Title

Hoffmann-La Roche Ltd ## Jun 2000 ## Apr 2007 ## Apr 2007 ## ## ## ## ## Interferon Alpha/ Beta Receptor ## (Cytokine Receptor Class II Member ## or Cytokine Receptor Family ## Member ## or Type I Interferon Receptor ## or IFNAR##) Agonist;

  • Drug Development
  • Interferon
  • Pharmaceutical
  • World
  • Product Initiative
  • Clinical Trial profile. 60 Trial Title

Hoffmann-La Roche Ltd ## Jul 2012 ## Jul 2012 ## Jul 2015 ## ## ## ## Interferon Alpha/ Beta Receptor ## (Cytokine Receptor Class II Member ## or Cytokine Receptor Family ## Member ## or Type I Interferon Receptor ## or IFNAR##) Agonist;

  • Clinical Trial
  • Interferon
  • Monoclonal Antibody
  • Therapy
  • Bristol-Myers Squibb Company
  • Target
  • Elastase or ELANE or EC 3.4.21.37)

Hoffmann-La Roche Ltd Bayer AG ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## Allergan Plc ## ## ## ## ## ## poractant alfa alone or in combination has the highest number of respiratory distress syndrome ongoing clinical trials.

  • Immunotherapy
  • Interferon
  • World
  • Product Initiative
  • Windtree Therapeutics, Inc.
  • NUMBER OF PRODUCTS BY STAGE AND MECHANISM OF ACTION, H1 2020
  • NUMBER OF PRODUCTS BY STAGE AND TARGET, H1 2020

LOWR- ## (LonafarnibWith and withoutRitonavir-##)was a parallel dose comparison study which randomized subjects to receive different doses of lonafarnib with or without ritonavir or pegylated interferon for four to twelve weeks.

  • Interferon
  • United States
  • World
  • Product Initiative
  • REPLICor Inc.
  • Clinical Trial profile. 152 Trial Title
  • Clinical Trial profile. 83 Trial Title

## ## ## ## United States ## ## ## ## ## ## ## ## Germany ## ## ## ## ## ## ## ## United Kingdom ## ## ## ## ## ## ## ## Italy ## ## ## ## ## ## ## ## Canada ## ## ## ## ## ## ## ## France ## ## ## ## ## ## ## ## CLINICA

  • Drug Development
  • Interferon
  • World
  • Product Initiative
  • Shionogi & Co., Ltd.
  • Clinical Trial profile. 12 Trial Title

Carlsson Research AB ## Jan 2014 ## Dec 2015 ## ## ## ##-Hydroxytryptamine Receptor ##A (## HT##A or Serotonin Receptor ##A or HTR##A) Agonist; D## Dopamine Receptor (Dopamine D## Receptor or DRD##) Agonist ##-Hydroxytryptamine Receptor ##A (## HT##A or Serotonin Receptor ##A or HTR##A); D## Dopamine Recept

  • Clinical Trial
  • Interferon
  • Monoclonal Antibody
  • World
  • Product Initiative
  • 5. All the trials included are unique trials.
  • Clinical Trial profile. 145 Trial Title

Those who switched from interferon beta-##a to OCREVUS experienced a significant decline in ARR and CDP## by year one that was maintained through year two.

  • Clinical Trial
  • Drug Development
  • Interferon
  • Neurological Disorder
  • Biogen Idec Inc.
  • interferon alpha - Drug Profile
  • in a novel solid unitary dosage form adapted to be dissolved in saliva when placed in the mouth.

The molecules developed by Companies in Phase II, Phase I and Preclinical stages are ##, ## and ## respectively.

  • Interferon
  • Medical Biotechnology
  • Therapy
  • World
  • Product Initiative
  • Target
  • Official Title

NC. ##. ## Central Nervous System Relapsing Remitting Multiple Sclerosis (RRMS) Completed Phase IV Interventional interferon beta-##b Lugano Regional Hospital - Civic ## Jun 2010 ## Nov 2011 ## ## ## ## ## Interferon Alpha/ Beta Receptor ## (Cytokine Receptor Class

  • Clinical Trial
  • Drug Development
  • Interferon
  • Neurological Disorder
  • Biogen Idec Inc.